Save 60% Off all remaining inventory with Promo Code: ICE

Notice of Allowance Rewarded to SciCann Therapeutics For Its Enhanced CBD Therapy

October 04, 2019

TORONTO and TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) — SciCann Therapeutics is pleased to announce that it has received a notice of allowance from the United States Patent and Trademarks Office (USPTO) for its US patent application covering the use of the proprietary SCN-002 enhanced CBD therapy for the treatment of NASH (non-alcoholic steatohepatitis).

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver due to causes other than alcohol use, while non-alcoholic steatohepatitis (NASH) is a type of NAFLD in which inflammation, fibrosis and liver cell damage occur as a result of the fat deposits accumulated in the liver tissue. Several health conditions prevalent in the western society, including obesity, metabolic syndrome and type 2 diabetes, are considered as risk factors for the development of NAFLD and NASH. No medicines have yet been approved by the FDA for the treatment of these conditions.

The SCN-002 drug candidate is a novel synergistic combination of CBD and an additional botanical anti-inflammatory compound that presumably also prevents fat accumulation in the liver tissue. Pre-clinical studies performed by SciCann have demonstrated substantial synergistic effects between the two components of its proprietary SCN-002 therapy for the treatment of NASH, with a five-fold increased efficacy comparing to CBD alone, as measured by reduction of liver inflammation markers and liver enzymes elevation levels in the model animals.

SciCann is currently preparing for the launch of a double blind, randomized, placebo-controlled phase II clinical study in a leading medical center in Israel to verify the safety and efficacy of the SCN-002 product for early to mid stage NASH patients.

Dr. Zohar Koren, Co-founder and CEO of SciCann Therapeutics, stated, “NAFLD is the most common liver disorder in developed countries with an estimate of 75 to 100 million Americans suffering from the disease, while NASH, the inflammatory and fibrotic derivative of NAFLD, affects around 15 to 20 million US patients[1]. NASH might lead to complications such as cirrhosis, liver cancer, liver failure and cardiovascular disease, and is expected to become the leading cause of need for a liver transplant in the western world over the next few years.

“The fact that no therapies have yet been approved specifically for these highly prevalent indications creates a huge unmet need for novel treatments targeting liver inflammation. The positive preclinical results we have obtained so far with the SCN-002 enhanced CBD product, together with the approval by the USPTO of the US patent application covering its use for the treatment of NASH, create a solid base for the further development of this revolutionary drug candidate for NASH patients under rigorous clinical studies to be launched in Israel in the near future.” 

[1] Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (January 2018). “Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention”. Nature Reviews. Gastroenterology & Hepatology. 15 (1): 11–20.

About SciCann Therapeutics
SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of inflammatory disorders, oncology and neurodegenerative diseases and develops a line of proprietary cannabinoid-based products for the treatment of chosen life-threatening conditions that present a high level of unmet need.
SciCann has created a network of collaborations with leading academic centers and medical institutions in Israel in order to engage in cutting edge science and rigorous clinical studies to develop its products, while using the permissive regulatory climate in Israel for performing its R&D programs quickly and efficiently.

Original article posted by Global News Wire

For more Press Releases, subscribe to the CBD Business Weekly Newsletter.

The post Notice of Allowance Rewarded to SciCann Therapeutics For Its Enhanced CBD Therapy appeared first on Cannadelics.





Also in Education

Owning Guns is a Constitutional Right, Unless You’re a Cannabis User

September 28, 2022

Take two of the most hot-button, tendentious issues of our time – cannabis use and gun rights – combine them, and now we really have a debate. As the law currently stands, medical cannabis patients are not afforded their 2nd amendment right to bear arms. Technically, all cannabis consumers are banned from buying guns, but only medical […]

The post Owning Guns is a Constitutional Right, Unless You’re a Cannabis User appeared first on Cannadelics.

Continue Reading

Cannabis policy changes in Africa are welcome. But small producers are the losers

September 28, 2022

TESTSTSARDSAR

Cannabis policy changes in Africa are welcome. But small producers are the losers by Clemence Rusenga

Cannabis is a drug crop with a long history in Africa. Alongside coca and opium poppy, it has been subjected to international control for nearly a century. The International Opium Convention of 1925 institutionalised the international control system and extended the scope of control to cannabis. In 1961 a new international convention was adopted to […]

A link to your site, with your site's name and description as anchor text.

Continue Reading

University of Sydney to Offer Free Cannabis Testing

September 27, 2022

TESTSTSARDSAR

University of Sydney to Offer Free Cannabis Testing by Johnny Green

The University of Sydney is launching a fairly robust study in an attempt to, as the university describes it, “investigate cannabis consumption, behaviours, and attitudes among users.” Part of the study involves offering free, anonymous cannabis testing for people that cultivate their own cannabis in the Australian Capital Territory (ACT). Cannabis was decriminalized in 2020 in the […]

A link to your site, with your site's name and description as anchor text.

Continue Reading

Inventory Clearance Sale

Save 60% Off all remaining inventory with Promo Code: ICE